US OptionsDetailed Quotes
AVTE250117C5000
- 0.05
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume5 Open Interest5.00Strike Price0.00Turnover359.10%IV98.04%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1069Delta0.1580Gamma51.00Leverage Ratio-0.0172Theta0.0000Rho5.45Eff Leverage0.0006Vega
Aerovate Stock Discussion
Sign in to post a comment
$Aerovate (AVTE.US)$ thanks in 2,40 out 2,89
2
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Aerovate (AVTE.US)$ good volume kick in
$Aerovate (AVTE.US)$ seems not good to me
$Aerovate (AVTE.US)$ not moving yet
1
$Aerovate (AVTE.US)$ Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
$Aerovate (AVTE.US)$
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
1
No comment yet
103892611 : yes
WeiTheSaint469 OP : thank God I got out lol